Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Sales of Investments
Cash received from selling or redeeming investments.
Sionna Therapeutics, Inc.NASDAQ: SION
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments grows, but more slowly than its trailing trend
Q1 FY2026 sales of investments of $50.15M rose 64.5% year over year, behind the +161.8% change in trailing-twelve-month sales of investments. Sequentially, it fell 23.6% from the prior quarter. Over 3 fiscal years it compounded at +151.4% a year.
Context
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +64.5% toward the trailing-twelve-month pace of +161.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 206.65M USD
- Year-over-year change
- +269.3%
- 3-year CAGR
- +151.4%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 206.65M | +269.3% |
| FY2024 | 2024-12-31 | 55.96M | +7.6% |
| FY2023 | 2023-12-31 | 52M | +300.0% |
| FY2022 | 2022-12-31 | 13M | — |
Sales of Investments vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 sales of investments of $226.31M is the 7th largest of the 11 companies compared; the peer median is $299.51M.
- Its year-over-year change of +161.8% is the 2nd highest of 10, against a peer median of -21.3%.
- Over three fiscal years its annual growth of +151.4% compares with a peer median of +28.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $502.67M | -21.3% | +28.6% | 448811.6% | |
| LTM Mar 2026 | $495.32M | +176.4% | +4.1% | 2291.8% | |
| LTM Jun 2026 | $492.8M | +18.2% | +86.5% | — | |
| LTM Sep 2026 | $353.02M | +68.0% | — | 132.7% | |
| LTM Jun 2026 | $350M | -46.3% | — | — | |
| LTM Sep 2026 | $249.02M | -57.5% | -0.3% | 367.0% | |
| LTM Mar 2026 | $226.31M | +161.8% | +151.4% | — | |
| LTM Mar 2026 | $214.68M | +18.6% | +46.7% | 50.2% | |
| LTM Sep 2026 | $54M | -81.1% | — | — | |
| LTM Mar 2026 | $47.5M | — | — | 237.5% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding SION) | $299.51M | -21.3% | +28.6% | 237.5% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.